Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may protect against vertebral fractures in people with diabetes, ...

As for this specific alternative, the weight loss results are “remarkable” so far, says Gitanjali Srivastava, MD, co-director ...

G protein-coupled receptors (GPCRs) are essential for cell signal transduction and comprise the largest drug target protein family. Upon agonist stimulation, these receptors activate multiple ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — In patients with metabolic-associated steatotic liver disease or metabolic-associated ...

Retatrutide, a new experimental weight-loss drug, targets three hormones and shows promising results far beyond current ...

Treatment with glucagon-like peptide-1 receptor agonists was associated with lower probabilities of heart, kidney, and lung complications after partial nephrectomy for RCC.

The complex pathophysiology of obesity requires a multidisciplinary approach that includes lifestyle and medical interventions for successful management. Anti-obesity medications (AOMs) have emerged ...

Genetic inactivation of the kidney glucagon receptor (GCGR) in mice causes abnormalities in renal health and metabolic dysregulation, with symptoms resembling those of chronic kidney disease (CKD) in ...

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 ...

Retatrutide treatment resulted in significant improvements in WOMAC pain scores and body weight compared with placebo in the TRIUMPH-4 trial.